Anna Barker1, Megan Duster2, Susan Valentine3, Laurie Archbald-Pannone4, Richard Guerrant5, Nasia Safdar6. 1. University of Wisconsin School of Medicine and Public Health, Department of Population Health Sciences, Madison, WI, USA. Electronic address: akbarker@wisc.edu. 2. University of Wisconsin, Madison, WI, USA. Electronic address: mnd@medicine.wisc.edu. 3. Department of Medicine, University of Wisconsin Hospital, Madison, WI, USA. Electronic address: svalentine@medicine.wisc.edu. 4. University of Virginia, School of Medicine, Department of Medicine, Division of General, Geriatric, Palliative, and Hospital Medicine, Charlottesville, VA, USA; University of Virginia, School of Medicine, Department of Medicine, Division of Infectious Diseases and International Health, Charlottesville, VA, USA. Electronic address: LA2E@hscmail.mcc.virginia.edu. 5. University of Virginia, School of Medicine, Department of Medicine, Division of Infectious Diseases and International Health, Charlottesville, VA, USA. Electronic address: rlg9a@virginia.edu. 6. Division of Infectious Diseases, Department of Medicine, University of Wisconsin Hospital, Madison, WI, USA; William S. Middleton Memorial Veterans Affairs Hospital, Madison, WI, USA; Department of Infection Control, University of Wisconsin Hospital and Clinics, Madison, WI, USA. Electronic address: ns2@medicine.wisc.edu.
Abstract
BACKGROUND: Clostridium difficile is a pathogen of rapidly increasing public health importance. An estimated quarter of a million Clostridium difficile infections (CDI) occur in the United States annually, at a resultant cost of 14,000 deaths and 1 billion dollars. Clostridium difficile related deaths have risen 400% over the last decade, and current standard antibiotic treatments are only 75 to 85% successful. Besides increasing the risk of antibiotic resistance and side effects, these treatments are very expensive. The most vulnerable population for Clostridium difficile is older adults, who make up approximately half of the cases, but account for 90% of the related deaths. Probiotics may have potential as adjunctive therapeutic agents for CDIs, however, current data is limited. METHODS: This pilot study is a single-site, randomized, placebo-controlled, double-blind, phase two clinical trial. The trial primarily evaluates the effect of four weeks of probiotic therapy in addition to standard of care on Clostridium difficile diarrhea duration and recurrence. Secondary outcomes include effect on fecal cytokines, fecal lactoferrin, and Clostridium difficile toxin density in stool, as well as patient functional status. DISCUSSION: This pilot study will determine the feasibility and effect size to conduct larger randomized controlled trials of probiotic interventions in patients with CDI, to determine the impact of probiotics on the symptoms of CDI. ClinicalTrials.gov Identifier: NCT01680874. Published by Elsevier Inc.
RCT Entities:
BACKGROUND:Clostridium difficile is a pathogen of rapidly increasing public health importance. An estimated quarter of a million Clostridium difficile infections (CDI) occur in the United States annually, at a resultant cost of 14,000 deaths and 1 billion dollars. Clostridium difficile related deaths have risen 400% over the last decade, and current standard antibiotic treatments are only 75 to 85% successful. Besides increasing the risk of antibiotic resistance and side effects, these treatments are very expensive. The most vulnerable population for Clostridium difficile is older adults, who make up approximately half of the cases, but account for 90% of the related deaths. Probiotics may have potential as adjunctive therapeutic agents for CDIs, however, current data is limited. METHODS: This pilot study is a single-site, randomized, placebo-controlled, double-blind, phase two clinical trial. The trial primarily evaluates the effect of four weeks of probiotic therapy in addition to standard of care on Clostridium difficilediarrhea duration and recurrence. Secondary outcomes include effect on fecal cytokines, fecal lactoferrin, and Clostridium difficile toxin density in stool, as well as patient functional status. DISCUSSION: This pilot study will determine the feasibility and effect size to conduct larger randomized controlled trials of probiotic interventions in patients with CDI, to determine the impact of probiotics on the symptoms of CDI. ClinicalTrials.gov Identifier: NCT01680874. Published by Elsevier Inc.
Authors: S P Borriello; W P Hammes; W Holzapfel; P Marteau; J Schrezenmeir; M Vaara; V Valtonen Journal: Clin Infect Dis Date: 2003-03-05 Impact factor: 9.079
Authors: Nadja Larsen; Finn K Vogensen; Rikke Gøbel; Kim F Michaelsen; Waleed Abu Al-Soud; Søren J Sørensen; Lars H Hansen; Mogens Jakobsen Journal: FEMS Microbiol Ecol Date: 2011-01-11 Impact factor: 4.194
Authors: Arthur C Ouwehand; Merja Nermes; Maria Carmen Collado; Nina Rautonen; Seppo Salminen; Erika Isolauri Journal: World J Gastroenterol Date: 2009-07-14 Impact factor: 5.742
Authors: Israel Lowy; Deborah C Molrine; Brett A Leav; Barbra M Blair; Roger Baxter; Dale N Gerding; Geoffrey Nichol; William D Thomas; Mark Leney; Susan Sloan; Catherine A Hay; Donna M Ambrosino Journal: N Engl J Med Date: 2010-01-21 Impact factor: 91.245
Authors: Alla Aroutcheva; Julie Auclair; Martin Frappier; Mathieu Millette; Karen Lolans; Danielle de Montigny; Serge Carrière; Stephen Sokalski; William E Trick; Robert A Weinstein Journal: Probiotics Antimicrob Proteins Date: 2016-03 Impact factor: 4.609